177 related articles for article (PubMed ID: 16818189)
1. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
Joudi FN; Smith BJ; O'Donnell MA;
Urol Oncol; 2006; 24(4):344-8. PubMed ID: 16818189
[TBL] [Abstract][Full Text] [Related]
2. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer.
O'Donnell MA; Lilli K; Leopold C;
J Urol; 2004 Sep; 172(3):888-93. PubMed ID: 15310991
[TBL] [Abstract][Full Text] [Related]
3. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
O'Donnell MA; Krohn J; DeWolf WC
J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
[TBL] [Abstract][Full Text] [Related]
4. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
6. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
[TBL] [Abstract][Full Text] [Related]
8. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
Bercovich E; Deriu M; Manferrari F; Irianni G
Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
[TBL] [Abstract][Full Text] [Related]
9. Intravesical immunotherapy for superficial bladder cancer.
Said MT; Abomelha MS; Orkubi SA
Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
[TBL] [Abstract][Full Text] [Related]
10. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.
Joudi FN; Smith BJ; O'Donnell MA; Konety BR
J Urol; 2006 May; 175(5):1634-9; discussion 1639-40. PubMed ID: 16600718
[TBL] [Abstract][Full Text] [Related]
11. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer.
Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R
Urology; 1996 Dec; 48(6):957-61; discussion 961-2. PubMed ID: 8973689
[TBL] [Abstract][Full Text] [Related]
14. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
15. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
17. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
18. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
[TBL] [Abstract][Full Text] [Related]
19. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
20. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
